Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Alan John Taylor Ph.D. | Executive Chairman | 539.68k | -- | -- |
| Mr. David K. Green BEc., CA | Chief Financial Officer | 151.46k | -- | -- |
| Dr. Colin David Biggin Ph.D. | COO & Non-Independent Executive Director | 432.7k | -- | -- |
| Ms. Michelle Parker | CEO, MD & Executive Director | -- | -- | -- |
| Dr. Matthew Harris BSc., M.B.A., Ph.D. | Chief Scientific Officer | 124.47k | -- | -- |
| Ms. Lisa Sadetskaya | Director of Corporate Communications. | -- | -- | -- |
| Mary Bennett | Head of People & Culture | -- | -- | -- |
| Mr. Shaemus Gleason | Executive Vice President of Operations | -- | -- | -- |
| Dr. Othon Gervasio | Chief Medical Officer | -- | -- | -- |
| Ms. Eva Lengyelova | Executive Vice President of Clinical Development | -- | -- | -- |
Clarity Pharmaceuticals Ltd
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 50
Description
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company's products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available